HIGHMARK WHOLECARE

Updated: 07/2023
PARP Approved: 09/2023

Prior Authorization Criteria

Livmarli (maralixibat)

All requests for Livmarli (maralixibat) require a prior authorization and will be screened for medical necessity and appropriateness using the criteria listed below.

Coverage may be provided with a diagnosis of **cholestatic pruritis** caused by **Alagille syndrome (ALGS)** and the following criteria is met:

- Member must be ≥ 3 months old
- Must be prescribed by or in consultation with a hepatologist or gastroenterologist
- Must have diagnosis confirmed by genetic testing
- Must provide documentation showing the member has tried and failed or had an intolerance or contraindication to ursodeoxycholic acid (Ursodiol)
- Must provide documentation showing the member has tried and failed or had an intolerance or contraindication to ONE of the following for symptomatic relief of pruritis:
    - Bile acid sequestrants (i.e. cholestyramine, colesevelam, or colestipol)
    - Rifampicin
    - Antihistamine
- Must provide baseline documentation of BOTH of the following:
    - Liver function tests
    - Fat-soluble vitamin levels
- The requested dose and frequency is in accordance with FDA-approved labeling, nationally recognized compendia, and/or evidence-based practice guidelines
- **Initial Duration of Approval:** 3 months
- **Reauthorization criteria**
    - Must submit LFTs within past 3 months
    - Must submit fat-soluble vitamin levels within past 3 months
    - Documentation of improvement of pruritus
    - Must provide dosing plan for continued use if no documented clinical benefit
- **Reauthorization Duration of Approval:** 12 months

Coverage may be provided for any non-FDA labeled indication if it is determined that the use is a medically accepted indication supported by nationally recognized pharmacy compendia or peer-reviewed medical literature for treatment of the diagnosis(es) for which it is prescribed. These requests will be reviewed on a case by case basis to determine medical necessity.

When criteria are not met, the request will be forwarded to a Medical Director for review. The physician reviewer must override criteria when, in their professional judgment, the requested medication is medically necessary.

HIGHMARK WHOLECARE

Updated: 07/2023
PARP Approved: 09/2023

LIVMARLI (MARALIXIBAT)
PRIOR AUTHORIZATION FORM

Please complete and fax all requested information below including any progress notes, laboratory test results, or chart documentation as applicable to Highmark Wholecare Pharmacy Services. **FAX:** (888) 245-2049
If needed, you may call to speak to a Pharmacy Services Representative. **PHONE**: (800) 392-1147 Mon – Fri 8:30am to 5:00pm

PROVIDER INFORMATION

Requesting Provider:	Provider NPI:
Provider Specialty:	Office Contact:
State license #:	Office NPI:
Office Address:	Office Phone:
	Office Fax:

MEMBER INFORMATION

Member Name:	DOB:	
Member ID:	Member weight:	Height:

REQUESTED DRUG INFORMATION

Medication:	Strength:	
Directions:	Quantity:	Refills:
Is the member currently receiving requested medication? ☐ Yes ☐ No	Date Medication Initiated:	

Billing Information

This medication will be billed: ☐ at a pharmacy **OR** ☐ medically, JCODE:_____

Place of Service: ☐ Hospital ☐ Provider's office ☐ Member's home ☐ Other

Place of Service Information

Name:	NPI:
Address:	Phone:

MEDICAL HISTORY (Complete for ALL requests)

Diagnosis:	ICD Code:

Has diagnosis been confirmed by genetic testing? ☐ Yes ☐ No
Is pruritis present? ☐ Yes ☐ No
Have baseline LFTs been checked? ☐ Yes ☐ No
Have baseline fat-soluble vitamin levels been checked? ☐ Yes ☐ No
What has been tried? Check all that apply and provide the information below.

☐ Ursodiol
☐ Rifampicin
☐ Bile acid sequestrant (e.g. cholestyramine, colesevelam)
☐ Antihistamines

CURRENT or PREVIOUS THERAPY

Medication Name	Strength/ Frequency	Dates of Therapy	Status (Discontinued & Why/Current)

REAUTHORIZATION

Have LFT's been checked within the past 3 months? ☐ Yes ☐ No
Have fat-soluble vitamin levels been checked within the past 3 months? ☐ Yes ☐ No

Has the member experienced an improvement of pruritis with treatment? ☐ Yes ☐ No

SUPPORTING INFORMATION or CLINICAL RATIONALE

Prescribing Provider Signature	Date